लोड हो रहा है...

Efficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled study

BACKGROUND: Combination of the inhaled long-acting muscarinic antagonist umeclidinium (UMEC; GSK573719) with the long-acting β(2)-agonist vilanterol (VI) is an approved maintenance treatment for COPD in the US and EU. We compared the efficacy and safety of UMEC/VI with placebo in patients with COPD...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Int J Chron Obstruct Pulmon Dis
मुख्य लेखकों: Zheng, Jinping, Zhong, Nanshan, Newlands, Amy, Church, Alison, Goh, Aik H
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Dove Medical Press 2015
विषय:
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC4562726/
https://ncbi.nlm.nih.gov/pubmed/26366068
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S81053
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!